PharmaCyte Biotech, Inc. (PMCB) stock

PMCBNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends April 30

Financials through Q1 FY2027, quarter ended Jul 31, 2026Last filing: 10-Q on Sep 14, 2026Score 7/30

$0.40+0.00 (+0.75%)

Close on Nov 12, 2026Market cap $4.32MP/E –Yield –

PharmaCyte Biotech gross margin

Gross margin is gross profit as a percentage of revenue.

For fiscal 2013 it was 20.9%, against 70.9% the year before.

Period	Period end	Value	Change (pts)
FY2013	Apr 30, 2013	20.9%	−50.0
FY2012	Apr 30, 2012	70.9%	−3.6
FY2011	Apr 30, 2011	74.5%	–

Parsed from the XBRL in PharmaCyte Biotech's annual and quarterly filings with the SEC
Per-share figures adjusted for the 1-for-1500 reverse split on Aug 10, 2021
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is PMCB.

Advertisement
300 × 250

See a number that looks wrong?